MCF Advisors LLC Sells 123 Shares of Johnson & Johnson (NYSE:JNJ)

MCF Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,148 shares of the company’s stock after selling 123 shares during the period. MCF Advisors LLC’s holdings in Johnson & Johnson were worth $2,293,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Boston Trust Walden Corp boosted its stake in Johnson & Johnson by 6.7% during the third quarter. Boston Trust Walden Corp now owns 1,093,709 shares of the company’s stock valued at $177,246,000 after buying an additional 69,028 shares during the last quarter. Global Wealth Management LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at approximately $1,789,000. Viewpoint Capital Management LLC grew its holdings in Johnson & Johnson by 4.9% during the 3rd quarter. Viewpoint Capital Management LLC now owns 13,370 shares of the company’s stock valued at $2,158,000 after buying an additional 621 shares in the last quarter. NorthCrest Asset Manangement LLC grew its holdings in Johnson & Johnson by 1.8% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 232,819 shares of the company’s stock valued at $37,731,000 after buying an additional 4,130 shares in the last quarter. Finally, Sageworth Trust Co grew its holdings in Johnson & Johnson by 91.7% during the 3rd quarter. Sageworth Trust Co now owns 7,777 shares of the company’s stock valued at $1,260,000 after buying an additional 3,720 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $160.88 on Monday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market capitalization of $387.19 billion, a P/E ratio of 10.03, a P/E/G ratio of 2.90 and a beta of 0.52. The stock has a 50 day moving average price of $163.41 and a 200 day moving average price of $155.10.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.93.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.